Phase 1 N=216 A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Number of Participants With Adverse Events (AEs) — 216; 120 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=120 Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults
Zika Virus
Primary: Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reaction (ARs)-First Vaccination — 0; 0; 0; 1 Participants
Phase 1 N=90 Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects
Zika Virus
Primary: Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 — 17; 20; 24; 0 Participants
Phase 1 N=9 Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
Sarcoma
Primary: Number of Participants Who Experienced Serious Adverse Events and Adverse Events — 4; 5 Participants
Phase 1 N=10 A Phased Clinical Trial of Dietary Supplemental Kava: Kava Pharmacokinetics
Pharmacokinetics
Primary: Time to Maximum Concentration of Kava in the Blood — 1.9; 1.2; 1.3; 1.2 hours
Phase 1 N=60 Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants
Chikungunya Virus
Primary: Part A: Number of Participants With Any Solicited Adverse Events (AEs) (Local and Systemic Reactogenicity Events) — 11; 10; 11; 10 Participants
Phase 1 N=60 Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children
Hookworm Disease · Hookworm Infection
Primary: Vaccine-Related Adverse Events — 8; 8; 8; 8 Participants
Phase 1 N=6 A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)
Sickle Cell Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 1; 3; 1; 0 Participants
Phase 1 N=24 A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants
Covid19
Primary: Part 1: Maximum Observed Serum Concentration (Cmax) of Sotrovimab Through Day 29 — 238.32; 188.66 Micrograms per milliliter
Phase 1 N=52 AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis
NASH - Nonalcoholic Steatohepatitis
Primary: Patient Incidence of Adverse Events for TERN-201 Versus Placebo — 9; 11; 8 Participants
Phase 1 N=14 Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention
Metastatic Melanoma
Primary: Percentage of Patients With Adverse Events (AEs) — 5; 4; 1; 0 Participants
Phase 1 N=54 Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial)
Hypertension
Primary: Change in Daytime Systolic Blood Pressure — 5.19; -2.71; -0.48 mmHg
Phase 1 N=74 Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine
Major Depressive Disorder
Primary: Number of Subjects With Adverse Events as a Measure of Safety and Tolerability of (2R,6R)-Hydroxynorketamine — 1; 0; 1; 1 Participants
Phase 1 N=24 Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)
Renal Dialysis · Kidney Failure, Chronic
Primary: Part 1: Percentage of Participants With Any Adverse Event (AE) — 16.7; 57.1; 66.7; 60.0 Percentage of Participants
Phase 1 N=12 Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants
Bioavailability
Primary: AUCinf of Nirmatrelvir Following the Administration of Nirmatrelvir/Ritonavir in Different Delivery Vehicles Under Fasted Conditions — 28670; 30780; 33170; 36020…